Furthermore, DFO treatment could decrease erythropoietin doses for anemia treatment, especially in patients with lower bone turnover, such as those with serum total alkaline phosphatase levels (< 60 U L−1) (Table 6). The gene discussed is EPO; the disease is anemia (phenotype).